{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:23:07Z","timestamp":1781076187478,"version":"3.54.1"},"reference-count":12,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["pathsocjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pathology CR"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We describe a collated data set of results from clinical testing of breast cancers carried out between 2009 and 2016 in the United Kingdom and Republic of Ireland. More than 199 000 patient biomarker data sets, together with clinicopathological parameters were collected. Our analyses focused on human epidermal growth factor receptor\u20102 (HER2), oestrogen receptor (ER) and progesterone receptor (PR), with the aim of the study being to provide robust confirmatory evidence on known associations in these biomarkers and to uncover new data on previously undescribed or unconfirmed associations, thus strengthening the evidence\u2010base in clinical breast cancer testing. Overall, 13.1% of tumours were HER2\u2010positive; 10.6% in ER\u2010positive tumours, and 25.5% in ER\u2010negative tumours. Higher rates of HER2 positivity were significantly associated with patient age &lt;56 years versus age \u226556 years, symptomatic versus screen\u2010detected tumours, testing of involved axillary node versus primary breast cancer, invasive ductal carcinoma (not otherwise specified) versus other histological types, higher histological grade, increasing tumour size, increasing nodal involvement, ER\u2010negative versus ER\u2010positive tumour status, PR\u2010negative versus PR\u2010positive tumour status. Where ER status was known, 82.7% of tumours were ER\u2010positive; 80.9% in women age &lt;56 years, and 83.6% in those age \u226556 years (ER\u2010positive cut\u2010off \u22651.0% positive tumour cells or equivalent). Where PR status was known, 64.9% of tumours were PR\u2010positive; 65.8% in women age &lt;56 years, and 64.4% in women age \u226556 years (PR\u2010positive cut off \u226510.0% or equivalent). These analyses of clinical test results provide contemporary benchmarking data for HER2, ER and PR positive rates.<\/jats:p>","DOI":"10.1002\/cjp2.112","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T09:11:49Z","timestamp":1533114709000},"page":"262-273","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients"],"prefix":"10.1002","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-2362","authenticated-orcid":false,"given":"Andrew","family":"Dodson","sequence":"first","affiliation":[{"name":"Ralph Lauren Centre for Breast Cancer Research The Royal Marsden Hospital  London UK"},{"name":"The Institute of Cancer Research  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Parry","sequence":"additional","affiliation":[{"name":"UK NEQAS ICC &amp; ISH University College London Cancer Institute  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merdol","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"UK NEQAS ICC &amp; ISH University College London Cancer Institute  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John MS","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Ontario Institute for Cancer Research  Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Pinder","sequence":"additional","affiliation":[{"name":"Cancer Studies, King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Dowsett","sequence":"additional","affiliation":[{"name":"Ralph Lauren Centre for Breast Cancer Research The Royal Marsden Hospital  London UK"},{"name":"The Institute of Cancer Research  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Miller","sequence":"additional","affiliation":[{"name":"UK NEQAS ICC &amp; ISH University College London Cancer Institute  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"UK\u2010NEQAS ICC & ISH. [Accessed 01 May 2018]. Available from:www.ukneqasiccish.org"},{"key":"e_1_2_8_3_1","volume-title":"Virchows Archiv","author":"Ibrahim M","year":"2011"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.0973"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28710"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202571"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2010.03533.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.9984"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqx063"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.756"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.08.031"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28222"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv159"}],"updated-by":[{"DOI":"10.1002\/cjp2.173","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T00:00:00Z","timestamp":1594080000000}}],"container-title":["The Journal of Pathology: Clinical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcjp2.112","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pathsocjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cjp2.112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:34:52Z","timestamp":1760304892000},"score":1,"resource":{"primary":{"URL":"https:\/\/pathsocjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cjp2.112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,21]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/cjp2.112"],"URL":"https:\/\/doi.org\/10.1002\/cjp2.112","archive":["Portico"],"relation":{"correction":[{"id-type":"doi","id":"10.1002\/cjp2.173","asserted-by":"object"}]},"ISSN":["2056-4538","2056-4538"],"issn-type":[{"value":"2056-4538","type":"print"},{"value":"2056-4538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,21]]},"assertion":[{"value":"2018-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}